This clinical trial is focused on studying the effects of a medication called Lebrikizumab on children and adolescents aged 6 months to under 18 years who have moderate-to-severe atopic dermatitis, commonly known as eczema. Eczema is a condition that makes the skin red, inflamed, and itchy. The study aims to evaluate how effective and safe Lebrikizumab is when used alongside topical corticosteroids, which are creams or ointments applied to the skin to reduce inflammation and irritation.

Participants in the study will receive either Lebrikizumab or a placebo, which is a substance with no active medication, to compare the outcomes. The treatment will be administered as a solution for injection under the skin. The study will monitor the participants over a period to assess improvements in their skin condition and any potential side effects. The goal is to determine if Lebrikizumab can significantly improve the symptoms of eczema compared to the placebo.

In addition to Lebrikizumab, the study will also consider the effects of other treatments such as glucocorticoids, which are oral medications that help reduce inflammation, and various types of topical corticosteroids, which vary in potency from weak to very potent. The study will help understand the best treatment options for managing moderate-to-severe eczema in young patients.